Suppr超能文献

阿片类药物与苯二氮䓬类药物/Z类药物联合处方与全因死亡率的关系——一项以初级保健为基础的纵向研究,最常开具的是弱阿片类药物

Co-prescribing of opioids and benzodiazepines/Z-drugs associated with all-cause mortality-A population-based longitudinal study in primary care with weak opioids most commonly prescribed.

作者信息

Linnet Kristjan, Thorsteinsdottir Heidrun Sjofn, Sigurdsson Johann Agust, Sigurdsson Emil Larus, Gudmundsson Larus Steinthor

机构信息

Development Centre for Primary Healthcare in Iceland, Primary Health Care of the Capital Area, Reykjavik, Iceland.

Faculty of Pharmaceutical Sciences, School of Health Sciences, University of Iceland, Reykjavik, Iceland.

出版信息

Front Pharmacol. 2022 Sep 6;13:932380. doi: 10.3389/fphar.2022.932380. eCollection 2022.

Abstract

The risk of mortality associated with the co-prescribing of benzodiazepines and opioids has been explored in a number of papers mainly focusing on strong opioids. The mortality risk associated with the use of weak opioids has not been dealt with to a similar extent. To assess the mortality risk in primary care patients with consistent 3-year co-prescribing of benzodiazepine/Z-drugs (benzodiazepine receptor modulators) and mainly weak opioids (codeine, tramadol). Of 221,804 patients contacting the primary healthcare centres, 124,436 were selected for further analysis, 88,832 participants fulfilled the inclusion criteria, aged 10-69 years and were divided into four groups with neither any use of benzodiazepines/Z-drugs nor opioids as Group 1, 3 years' use of opioids and no/minimal benzodiazepines/Z-drugs as Group 2, with benzodiazepines/Z-drugs and no/minimal opioids as Group 3, and finally both benzodiazepines/Z-drugs and opioids as Group 4. Hazard ratios were calculated with the no-drug group as a reference, using Cox proportional hazards regression model adjusted for age, sex, number of chronic conditions and cancer patients excluded (n = 87,314). Hazard ratios for mortality increased both in Group 3 where it was 2.66 (95% CI 2.25-3.09) and in Group 4 where it was 5.12 (95% CI 4.25-6.17), with increased dose and higher number of chronic conditions. In Group 4 an opioid dose-dependent increase in mortality among persons using >1000 DDDs benzodiazepines/Z-drugs was observed when those on less than ≤300 DDDs of opioids with HR 4.94 (95% CI 3.54-6.88) were compared to those on >300 DDDs with HR 7.61/95% CI 6.08-9.55). This increase in mortality was not observed among patients on <1000 DDDs of benzodiazepines/Z-drugs. The study supports evidence suggesting that mortality increases in a dose-dependent manner in patients co-prescribed benzodiazepines/Z-drugs and weak opioids (codeine, tramadol). An association between the number of chronic conditions and a rise in mortality was found. Long-term use of these drugs should preferably be avoided. Non-pharmacological therapy should be seriously considered instead of long-term use of benzodiazepines/Z-drugs, and deprescribing implemented for chronic users of these drugs when possible.

摘要

许多论文探讨了苯二氮䓬类药物与阿片类药物联合处方相关的死亡风险,这些论文主要关注强效阿片类药物。而与使用弱阿片类药物相关的死亡风险在类似程度上未得到研究。为评估在初级保健患者中,苯二氮䓬类药物/Z类药物(苯二氮䓬受体调节剂)与主要是弱阿片类药物(可待因、曲马多)持续联合处方3年的死亡风险。在221,804名联系初级医疗保健中心的患者中,124,436名被选作进一步分析,88,832名参与者符合纳入标准,年龄在10至69岁之间,被分为四组:既未使用苯二氮䓬类药物/Z类药物也未使用阿片类药物的为第1组,使用阿片类药物3年且未使用/极少使用苯二氮䓬类药物/Z类药物的为第2组,使用苯二氮䓬类药物/Z类药物且未使用/极少使用阿片类药物的为第3组,最后同时使用苯二氮䓬类药物/Z类药物和阿片类药物的为第4组。以未用药组为参照,使用经年龄、性别、慢性病数量和排除癌症患者(n = 87,314)调整的Cox比例风险回归模型计算风险比。第3组的死亡风险比增加至2.66(95%置信区间2.25 - 3.09),第4组为5.12(95%置信区间4.25 - 6.17),且随着剂量增加和慢性病数量增多而升高。在第4组中,当比较使用>1000限定日剂量(DDD)苯二氮䓬类药物/Z类药物且使用少于≤300 DDD阿片类药物的人群(风险比4.94,95%置信区间3.54 - 6.88)与使用>300 DDD阿片类药物的人群(风险比7.61/95%置信区间6.08 - 9.55)时,观察到使用阿片类药物的人群死亡率呈剂量依赖性增加。在使用<1000 DDD苯二氮䓬类药物/Z类药物的患者中未观察到这种死亡率增加情况。该研究支持如下证据,即苯二氮䓬类药物/Z类药物与弱阿片类药物(可待因、曲马多)联合处方的患者死亡率呈剂量依赖性增加。发现慢性病数量与死亡率上升之间存在关联。应尽量避免长期使用这些药物。应认真考虑非药物治疗而非长期使用苯二氮䓬类药物/Z类药物,并在可能的情况下对这些药物的长期使用者实施减药。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7c1/9485885/9bf4ecc4a353/fphar-13-932380-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验